PPD, ERT In Strategic Data Solutions Pact

PPD and ERT entered a strategic partnership to facilitate delivery of ERT’s patient safety and efficacy endpoint data collection solutions for biopharma clients. The companies will work together on all areas of the clinical development process to align crucial aspects of service delivery, including budget and proposal development, study startup, data management and invoicing.
 
The agreement expands PPD’s integrated resources spanning drug development from early phase studies through regulatory approval. PPD’s operations and global footprint offer ERT an opportunity to expand its reach and provide increased efficiencies in clinical trial deployment as it grows its customer base.
 
“ERT’s advanced technology in centralized cardiac safety, respiratory services and clinical outcome assessments (COA) complements PPD’s robust client offerings across our Phase I-IV clinical trials business,” said Paul Colvin, PPD’s executive vice president of clinical development. “ERT has an exemplary reputation in providing these services, and this partnership enhances PPD’s development capabilities across all therapeutic areas, with distinct advantages for respiratory, cardiovascular and late phase trials.”
 
“ERT is proud to partner with PPD, a global leader in clinical development,” said Jim Corrigan, president and chief executive officer of ERT. “PPD and ERT share a common vision of transforming drug development through the power of technology and clinical services. The combined expertise, experience and commitment to client success of ERT and PPD will help drive industry innovation and the development of new therapies.”